相关实验视频

Updated: Jul 17, 2025

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury

Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury

Published on: September 7, 2018

评估在狗中产生血栓的评价给予克洛皮多格瑞尔

Kaitlyn Rank¹, Alex M Lynch¹, Laura K Ruterbories¹

¹Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States.

Frontiers in veterinary science

|September 8, 2023

概括

在使用对血小板贫乏血进行血栓生成 (TG) 试验的狗中,克洛皮多格勒的监测没有显示出显著的变化. 这表明TG测定可能不是评估皮格瑞尔的可靠工具.

科学领域:

兽医医学兽医医学兽医医学
药理学药理学是指药理学的学科.
血液静止血液静止血液静止

背景情况:

克洛皮多格雷尔的抗血小板作用因人而异,需要监测.
血小板造影 (TEG) -血小板映射 (TEG-PM) 测定监测克洛皮多格勒,但缺乏广泛的可用性.
血栓生成 (TG) 试验为监测抗血小板药物效应提供了潜在的替代方案.

研究的目的:

在克洛皮多格雷尔注射之前和之后,评估狗的血栓生成 (TG) 测试变量 (延迟时间,峰值,ETP).
将TG测定结果与TEG-血小板映射 (TEG-PM) 变量 (MA-ADP,百分比抑制) 进行比较.
评估TG测试对监测皮格瑞尔在狗中的抗血小板作用的有用性.

主要方法:

在一项涉及6只健康狗的试点研究中,克洛皮多格雷尔治疗持续了7天.
在基线和治疗后采集的血液样本用于血小板计数,TG测定和TEG-PM.
使用Student的t-test进行统计比较,分析试验变量的变化.

主要成果:

在克洛皮多格雷尔治疗后的血小板贫乏血中,没有观察到TG测定变量 (延迟时间,峰值,ETP) 的显著变化 (p > 0.05).
观察到TEG MA-ADP显著下降 (p=0.04) 和百分比抑制的增加 (p=0.02),表明血小板抑制.
克洛皮多格雷尔的使用改变了TEG-PM变量,但在血小板贫乏血中没有改变TG测定变量.

结论:

在缺乏血小板的血上进行的血栓生成试验并没有反映克洛皮多格雷尔对狗的抗血小板作用.
这些发现表明,使用血小板贫乏血进行TG测定可能不是监测犬类患者用克洛皮多格雷尔治疗的合适方法.
可能需要进一步的研究来探索用富血小板血或其他方法进行TG测定,以便在狗中有效监测克洛皮多格雷尔.

关键词:

这是一种抗血栓的抗血栓药物.狗类犬类动物狗类犬类凝血是凝固的过程.血小板抑制剂血小板抑制剂治疗监测治疗监测.

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...